ClinicalTrials.gg

Program

tocilizumab

Also written as “Tocilizumab”, “tocilizumab [RoActemra/Actemra]” and “MRA(Tocilizumab)”.

Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · COVID-19 · Scleroderma, Systemic · Giant Cell Arteritis, led by 9 companies.

Furthest: phase 4, since Nov 9, 2009129 company-led studies, 4 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche1162 open or runningphase 4since Nov 9, 2009Mar 25, 2005Jul 30, 2027phase 2 · NCT04524871
Bio-Thera Solutions30 open or runningphase 3since Jan 22, 2019Jul 12, 2018none ahead
Bristol-Myers Squibb22 open or runningphase 3since Jan 9, 2026Feb 7, 2025Nov 14, 2028phase 3 · NCT07335562
Fresenius Kabi20 open or runningphase 3since Aug 11, 2020Aug 30, 2017none ahead
JW Pharmaceutical20 open or runningphase 3since Sep 29, 2010Sep 29, 2010none ahead
Beijing VDJBio10 open or runningphase 2since Jul 11, 2023Jul 11, 2023none ahead
Biogen10 open or runningphase 1since Feb 8, 2024Feb 8, 2024none ahead
Celltrion10 open or runningphase 3since Feb 2, 2023Feb 2, 2023none ahead
Mycenax Biotech10 open or runningphase 1since Apr 11, 2018Apr 11, 2018none ahead

Also a collaborator on its studies: Gilead Sciences, Pfizer, adagene-inc, tempest-therapeutics, nikang-therapeutics-inc and immune-onc-therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jul 30, 2012.

  1. Apr 19, 2019Phase 1 study in Giant Cell ArteritisHoffmann-La Roche · NCT03923738 · 24 enrolled · Switzerland
  2. Mar 23, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04320615 · 452 enrolled · United States, Canada, Denmark and more
  3. Apr 21, 2020Phase 2 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04363736 · 97 enrolled · United States
  4. Apr 29, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04372186 · 377 enrolled · United States, Brazil, Kenya and more
  5. May 28, 2020Phase 3 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04409262 · 649 enrolled · United States, Brazil, Russian Federation and more
  6. Aug 11, 2020Phase 3 study in Arthritis, RheumatoidFresenius Kabi · NCT04512001 · 604 enrolled · Bulgaria, Czechia, Georgia and more
  7. Aug 21, 2020Phase 2 study in Advanced Liver CancersHoffmann-La Roche · NCT04524871 · 518 enrolled · United States, China, France and more
  8. Dec 16, 2021Phase 1 study in COVID-19Hoffmann-La Roche · NCT05164133 · 2 enrolled · United States, Brazil, Croatia and more
  9. Feb 2, 2023Celltrion's first study: phase 3 study in Arthritis, RheumatoidNew to CelltrionCelltrion · NCT05725434 · 30 enrolled
  10. Jul 11, 2023Beijing VDJBio's first study: phase 2 study in Arthritis, RheumatoidNew to Beijing VDJBioBeijing VDJBio · NCT05957107 · 181 enrolled · China
  11. Jul 20, 2023Phase 1 study in Healthy MenBio-Thera Solutions · NCT05968508 · 300 enrolled · China
  12. Feb 8, 2024Biogen's first study: phase 1 study in Healthy VolunteerNew to BiogenBiogen · NCT06262477 · 300 enrolled · United States, United Kingdom
  13. Feb 7, 2025Bristol-Myers Squibb's first study: phase 1 study in Autoimmune DiseasesNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT07115745 · 125 planned · United States, Australia, Brazil and more
  14. Jan 9, 2026Phase 3 study in Scleroderma, SystemicPhase 3 reachedBristol-Myers Squibb · NCT07335562 · 92 planned · United States, Belgium, Canada and more

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in Advanced Liver CancersHoffmann-La Roche · NCT04524871
  2. Nov 14, 2028Primary completion: phase 3 study in Scleroderma, SystemicBristol-Myers Squibb · NCT07335562
  3. Mar 15, 2029Primary completion: phase 1 study in Autoimmune DiseasesBristol-Myers Squibb · NCT07115745
  4. Sep 30, 2030Primary completion: phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT03424005

TargetBeta

IL6R →read by rule
“A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity”NCIt, by rule
“Interleukin-6 receptor alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on IL6R

ProgramCompanyFurthest phaseStudies
sarilumabruleSanofiphase 427

Studies

The newest 60 of 129 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07335562Scleroderma, Systemic · United States, Belgium, Canada and more3Not yet recruitingBristol-Myers SquibbNov 14, 202892
NCT07115745Autoimmune Diseases · United States, Australia, Brazil and more1RecruitingBristol-Myers SquibbMar 15, 2029125
NCT06262477Healthy Volunteer · United States, United Kingdom1CompletedBiogenSep 25, 2024300
NCT05968508Healthy Men · China1CompletedBio-Thera SolutionsOct 8, 2024300
NCT05957107Arthritis, Rheumatoid · China2CompletedBeijing VDJBioJun 2, 2023181
NCT05725434Arthritis, Rheumatoid3UNKNOWNCelltrionApr 1, 202330
NCT05164133COVID-19 · United States, Brazil, Croatia and more1CompletedHoffmann-La RocheMar 27, 20242
NCT04524871Advanced Liver Cancers · United States, China, France and more2Active, not recruitingHoffmann-La RocheJul 30, 2027518
NCT04512001Arthritis, Rheumatoid · Bulgaria, Czechia, Georgia and more3CompletedFresenius KabiAug 31, 2021604
NCT04409262COVID-19 Pneumonia · United States, Brazil, Russian Federation and more3CompletedHoffmann-La RocheFeb 1, 2021649
NCT04372186COVID-19 Pneumonia · United States, Brazil, Kenya and more3CompletedHoffmann-La RocheAug 18, 2020377
NCT04363736COVID-19 Pneumonia · United States2CompletedHoffmann-La RocheAug 12, 202097
NCT04320615COVID-19 Pneumonia · United States, Canada, Denmark and more3CompletedHoffmann-La RocheJun 24, 2020452
NCT03923738Giant Cell Arteritis · Switzerland1CompletedHoffmann-La RocheNov 12, 202024
NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more2TerminatedHoffmann-La RocheOct 8, 2025272
NCT03830203Arthritis, Rheumatoid · China3CompletedBio-Thera SolutionsJan 5, 2021621
NCT03606876Arthritis, Rheumatoid · China1CompletedBio-Thera SolutionsJul 17, 2019138
NCT03522012Pharmacokinetics · Australia1CompletedMycenax BiotechSep 26, 2018190
NCT03424005Breast Neoplasms · United States, Australia, France and more2RecruitingHoffmann-La RocheSep 30, 20301,132
NCT03301883Arthritis, Juvenile · China4CompletedHoffmann-La RocheSep 4, 202162
NCT03282851Healthy · New Zealand1CompletedFresenius KabiOct 1, 2019696
NCT03202368Giant Cell Arteritis · France3CompletedHoffmann-La RocheAug 21, 20193
NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more2CompletedHoffmann-La RocheFeb 27, 2025341
NCT03155347Arthritis, Rheumatoid · China3CompletedHoffmann-La RocheAug 8, 2022340
NCT02682823Arthritis, Rheumatoid · United States4CompletedHoffmann-La RocheJul 29, 201691
NCT02678988Healthy Volunteer · United States1CompletedHoffmann-La RocheJun 2016189
NCT02573012Arthritis, Rheumatoid · France, Germany, Italy and more4CompletedHoffmann-La RocheFeb 9, 2018314
NCT02453256Scleroderma, Systemic · United States, Argentina, Belgium and more3CompletedHoffmann-La RocheJan 15, 2018212
NCT02336048Leukemia, Lymphocytic, Chronic, B-Cell · Israel, Italy, Latvia and more1TerminatedHoffmann-La RocheSep 21, 201838
NCT02165345Arthritis, Juvenile · United States, Argentina, Australia and more1CompletedHoffmann-La RocheNov 24, 202182
NCT02046616Arthritis, Rheumatoid · Denmark, Finland, Norway and more3CompletedHoffmann-La RocheSep 13, 2016133
NCT02046603Arthritis, Rheumatoid · United Kingdom3CompletedHoffmann-La RocheAug 4, 2016162
NCT02031471Arthritis, Rheumatoid · Belgium, Luxembourg3CompletedHoffmann-La RocheSep 201557
NCT02011334Arthritis, Rheumatoid · Argentina, Brazil, Colombia and more3CompletedHoffmann-La RocheOct 2016285
NCT02010216Arthritis, Rheumatoid · Kazakhstan4CompletedHoffmann-La RocheJul 201023
NCT02001987Arthritis, Rheumatoid · France3CompletedHoffmann-La RocheDec 2015139
NCT01991990Healthy Volunteer · United Kingdom4CompletedHoffmann-La RocheDec 201418
NCT01987479Arthritis, Rheumatoid · Netherlands3CompletedHoffmann-La RocheMay 26, 2016150
NCT01995201Arthritis, Rheumatoid · Ireland, Portugal, Spain3CompletedHoffmann-La RocheJul 2015401
NCT01988012Arthritis, Rheumatoid · Israel3CompletedHoffmann-La RocheJul 2015100
NCT01951170Arthritis, Rheumatoid · Australia3CompletedHoffmann-La RocheAug 201552
NCT01941940Arthritis, Rheumatoid · Italy3CompletedHoffmann-La RocheSep 9, 2015227
NCT01941095Arthritis, Rheumatoid · Greece3CompletedHoffmann-La RocheJul 10, 2016100
NCT01904292Arthritis, Juvenile · United States, Argentina, Australia and more1CompletedHoffmann-La RocheJun 13, 201752
NCT01904279Arthritis, Juvenile · United States, Argentina, Australia and more1CompletedHoffmann-La RocheMay 201652
NCT01878318Arthritis, Rheumatoid4WithdrawnHoffmann-La RocheJun 20150
NCT01791153Giant Cell Arteritis · United States, Belgium, Canada and more3CompletedHoffmann-La RocheApr 11, 2016251
NCT01772316Arthritis, Rheumatoid · Spain3CompletedHoffmann-La RocheMay 201547
NCT01734382Arthritis, Juvenile · United States, Argentina, Canada and more4CompletedHoffmann-La RocheOct 9, 201935
NCT01734993Arthritis, Rheumatoid · France3CompletedHoffmann-La RocheSep 201511
NCT01730456Arthritis, Rheumatoid · North Macedonia3CompletedHoffmann-La RocheMay 201513
NCT01727986Arthritis, Juvenile · Brazil3CompletedHoffmann-La RocheNov 201511
NCT01715831Arthritis, Rheumatoid · Brazil4CompletedHoffmann-La RocheJun 6, 201626
NCT01673919Arthritis, Juvenile · France3CompletedHoffmann-La RocheJan 20147
NCT01668966Arthritis, Rheumatoid · Brazil3CompletedHoffmann-La RocheMay 11, 201623
NCT01667471Arthritis, Juvenile · Germany3CompletedHoffmann-La RocheAug 20136
NCT01665430Arthritis, Rheumatoid · Poland3TerminatedHoffmann-La RocheFeb 201538
NCT01664598Arthritis, Rheumatoid · Russian Federation3CompletedHoffmann-La RocheJun 201549
NCT01662063Arthritis, Rheumatoid · United States, Puerto Rico3CompletedHoffmann-La RocheApr 2014218
NCT01655381Arthritis, Rheumatoid · France3CompletedHoffmann-La RocheJul 201515

How it is read

Names in the registry

  • “Tocilizumab”, 54 entries
  • “tocilizumab [RoActemra/Actemra]”, 47 entries
  • “MRA(Tocilizumab)”, 11 entries
  • “tocilizumab”, 6 entries
  • “MSB11456”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.